Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes

International Immunology

Volumn 10, Issue 12, 1998, Pages 1907-1916

  Agrawal, Babita ^a   Krantz, Mark J ^a   Reddish, Mark A ^a,b   Longenecker, B Michael ^a  

^a Biomira Inc   (Canada)

^b ID Vaccine   (United States)

Author keywords

Antigen; Cytotoxic T lymphocyte; Epitope; Immunomodulators; Immunotherapy; Peptide; T lymphocytes

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 4; LIPOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MUCIN;

ADENOCARCINOMA; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 0031701743     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/10.12.1907     Document Type: Article

References (38)

1. Barnd, D. L., Lan, M. S., Metzgar, R. S. and Finn, O. J. 1989. Specific major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc. Natl Acad. Sci. USA 86:7159.
2. Agrawal, B., Reddish, M. A., Krantz, M. J. and Longenecker, B. M. 1995. Does pregnancy immunize against breast cancer? Cancer Res. 55:2257.
3. Agrawal, B., Krantz, M. J., Reddish, M. A. and Longenecker, B. M. 1998. Cancer-associated MUC1 mucin inhibits human T cell proliferation which is reversible by IL-2. Nature Med. 4:43.
4. Hull, S. R., Bright, A., Carraway, K. L., Abe, M., Hayes, D. F. and Kufe, D. W. 1989. Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinoma cell line. Cancer Commun. 1:261.
5. Burchell, J., Gendler, S., Taylor-Papadimitriou, J., Girling, A., Lewis, A., Millis, R, and Lamport, D. 1987. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res. 47:5476.
6. + lymphocytes correlate with effects of THERATOPE® sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol. Immunother. 42:303.
7. MacLean, G. D., Reddish, M. and Longenecker, B. M. 1997. Prognostic significance of pre-immunotherapy serum CA27.29 (MUC-1) mucin level following active specific immunotherapy of metastatic adenocarcinoma patients. J. Immunother 20:70.
8. Jerome, K. R., Barnd, D. L., Bendt, K. M., Boyer, C. M., Taylor-Papadimitriou, J., McKenzie, I. F. C., Bast, R. C., Jr and Finn, O. J. 1991. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 51:2908.
9. Apostolopoulos, V., Osinki, C. and McKenzie, I. F. C. 1998. MUC1 cross-reactive Galα(1,3)Gal antibodies in humans switch immune responses from cellular to humoral. Nature Med. 4:315.
10. Reddish, M. A., MacLean, G. D., Koganty, R. R., Kan-Mitchell, J., Jones, V., Mitchell, M. S. and Longenecker, B. M. 1998. Anti-MUC1 class I restricted CTL in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int. J. Cancer, in press.
11. Fontenot, J. D., Tjandra, N., Bu, D., Ho, C., Montelaro, R. C. and Finn, O. J. 1993. Biophysical characterization of one-, two-, and three- tandem repeats of human mucin (MUC-1) protein core. Cancer Res. 53:5386.
12. DeBruijn, M. L. H., Schumacher, T. N. M., Neiland, J. D., Ploegh, H. L., Kast, W. M. and Melief, C. J. M. 1991. Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses. Eur. J. Immunol. 21:2963.
13. DeBruijn, M. L. H., Neiland, J. D., Schumacher, T. N. M., Ploegh, H. L., Kast, W. M. and Melief, C. J. M. 1992. Mechanisms of induction of primary virus-specific cytotoxic T lymphocyte responses. Eur. J. Immunol. 22:3013.
14. Stauss, H. J., Davis, H., Sadovnikova, E., Chain, B., Horowitz, N. and Sinclair, C. 1992. Induction of cytotoxic T lymphocytes with peptide in vitro: identification of candidate T cell epitopes in human papilloma virus. Proc. Natl Acad. Sci. USA 89:7871.
15. Houbiers, J. G. A., Nijman, H. W., Van der Burg, S. H., Drijfhout, J. W., Kenemans, P., van de Velde. C. J. H., Brand, A., Momburg, F., Cast, W. M. and Melief, C. J. M. 1993. In vitro induction of human cytotoxic T lymphocytes responses against peptides of mutant and wild type p53. Eur. J. Immunol. 23:2072.
16. Alexander, M. A., Damico, C. A., Wieties, K. M., Hansen, T. H. and Connolly, J. M. 1991. Correlation between CD8 dependency and determinant density using peptide-induced Ld-restricted cytotoxic T lymphocytes. J. Exp. Med. 173:849.
17. Carbone, F. R., Moore, M. W., Sheil, J. M. and Bevan, M. J. 1988. Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides. J. Exp. Med. 167:1767.
18. + CTL from naive precursors. J. Immunol. 153:996.
19. Macatonia, S. E., Taylor, P. M., Knight, S. D. and Askonas, B. A. 1989. Primary stimulation by dendritic cell induces anti-viral proliferative and cytotoxic T cell responses in vitro. J. Exp. Med. 169:1255.
20. Macatonia, S. E., Patterson, S. and Knight, S. D. 1991. Primary proliferative and cytotoxic T cell responses to HIV-induced in vitro by dendritic cells. Immunology 74:399.
21. Nair, S., Zhou, R, Reddy, R., Huang, L. and Rouse, B. T. 1992. Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induces primary cytotoxic T lymphocytes responses in vitro. J. Exp. Med. 175:609.
22. Nair, S., Babu, J. S., Dunham, R. G., Kanda, P., Burke, R. L. and Rouse, B. T. 1993. Induction of primary, antiviral, cytotoxic, and proliferative responses with antigens administered via dendritic cells J. Virol. 67:4062.
23. Steinman, R. M. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271.
24. Townsend, A. and Bodmer, H. 1989. Antigen recognition by class I-restricted T lymphocytes. Annu. Rev. Immunol. 7:601.
25. Agrawal, B., Reddish, M. A. and Longenecker, B. M. 1996. In vitro induction of MUC1 peptide-specific type-1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors. J. Immunol. 156:2089.
26. Domenech, N., Henderson, R. A. and Finn, O. J. 1995. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J. Immunol. 155:4766.
27. Townsend, A., Ohlen, C., Bastin, J., Ljunggren, H. G. and Karre, K. 1989. Association of class I major histocompatibility heavy and light chain induced by viral peptides. Nature 340:443.
28. Unanue, E. R. and Allen, P. M. 1987. The basis for the immunoregulatory role of macrophages and other accessory cells. Science 236:551.
29. Harding, C. V., Collins, D. and Unanue, E. R. 1991. Liposome encapsulated antigens engender lysosomal processing for class II presentation and cytosolic processing for class I presentation. J. Immunol. 147:2860.
30. Zhou, F. and Huang, L. 1994. Liposome-mediated cytoplasmic delivery of proteins: an effective means of accessing the MHC class I restricted antigen presentation pathway. Immunomethods 4:229
31. Longenecker, B. M. and Maclean, G. D. 1993. Prospects for mucin epitopes in cancer vaccines, Immunologists 1:89.
32. Ioannides C. G., Fisk, B., Jerome, K. R., Irimura, T., Wharton, J. T. and Finn, O. J. 1993. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol. 151:3693.
33. Samuel, J., Budzynski, W. A., Reddish, M. A., Ding, L., Zimmermann, G. L., Krantz, M. J., Koganty, R. R. and Longenecker, B. M. 1998. Immunogenicity and antitumor activity of a liposomal MUC1 peptide based vaccine. Int. J. Cancer 75:295.
34. Nair, S. K., Boczkowski, D., Snyder, D. and Gilboa, E. 1997. Antigen presenting cells pulsed with unfractionated tumor derived peptides are potent tumor vaccines. Eur. J. Immunol. 27:589.
35. Zitvogel, L., Myordomo, J. I., Tjandrawan, T., DeLeo, A. B., Clarke, M. R., Lotze, M. T. and Storkus, W. J. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and helper T cell 1-associated cytokines. J. Exp. Med. 183:87.
36. Bartels, C. J., Rosenberg, S. A. and Yang, J. C. Adoptive cellular immunotherapy of cancer in mice using allogeneic T cells. 1996. Ann. Surg. Oncol. 3:67.
37. Tsang, K, Y., Zaremba, S., Nieroda, C. A., Zhu, M. Z., Hamilton, J. M. and Schlom, J. 1995. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia CEA vaccine. J. Natl Cancer Inst. 87:982.
38. Correale, P., Walmsley, K., Nieroda, C., Zaremba, S., Zhu, M. and Schlom, J. 1997. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from human prostate antigen J. Natl Cancer Inst. 89:293.